- Home
- OMER
OMER
Omeros Corporation
as of 02-03-2026 3:38pm EST
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 894.8M | IPO Year: | 2009 |
| Target Price: | $32.50 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.95 - $17.65 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered OMER Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Omeros Corporation (OMER)
VP, Finance & CAO
Avg Cost/Share
$12.31
Shares
30,000
Total Value
$369,315.00
Owned After
0
SEC Form 4
VP, Finance & CAO
Avg Cost/Share
$12.72
Shares
30,000
Total Value
$381,600.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Borges David J. | OMER | VP, Finance & CAO | Jan 13, 2026 | Sell | $12.31 | 30,000 | $369,315.00 | 0 | |
| Borges David J. | OMER | VP, Finance & CAO | Jan 12, 2026 | Sell | $12.72 | 30,000 | $381,600.00 | 0 |
Compare OMER vs Leading Stocks
See how OMER stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.